RHOPRESSA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RHOPRESSA (RHOPRESSA).
Selective alpha-2 adrenergic receptor agonist; reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
| Metabolism | Partially metabolized in the liver by aldehyde dehydrogenase and glucuronidation; primarily excreted unchanged in urine. |
| Excretion | Primarily hepatic metabolism via CYP2C9 and CYP3A4; renal excretion accounts for <1% of unchanged drug; biliary/fecal excretion accounts for approximately 60% of the dose as metabolites. |
| Half-life | Terminal elimination half-life is approximately 45 minutes following topical ophthalmic administration, with clinical IOP-lowering effect persisting beyond 24 hours due to receptor binding kinetics. |
| Protein binding | Approximately 98% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.25 L/kg, indicating limited extravascular distribution, consistent with its high protein binding and topical route. |
| Bioavailability | Systemic bioavailability after topical ocular administration is low, approximately 0.001% due to extensive ocular metabolism and nasolacrimal drainage. |
| Onset of Action | Onset of IOP reduction occurs within 1-2 hours after topical ophthalmic administration. |
| Duration of Action | Duration of IOP-lowering effect is at least 24 hours, supporting once-daily dosing; peak effect observed at 8-12 hours post-dose. |
One drop of 0.02% ophthalmic solution in the affected eye(s) three times daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Not established; safety and efficacy in pediatric patients have not been studied. |
| Geriatric use | No significant differences in safety or efficacy observed; no specific dose adjustment recommended. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RHOPRESSA (RHOPRESSA).
| Breastfeeding | Excretion in human milk unknown; M/P ratio not available. Caution due to potential for vasoconstriction in infant; alternative agents preferred. |
| Teratogenic Risk | No adequate human studies; animal studies show no evidence of teratogenicity. Risk cannot be excluded; use only if benefit outweighs risk. First trimester: theoretical risk based on prostaglandin analog class. Second/third trimester: no specific data. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to netarsudil or any component of the formulation","Active ocular inflammation (e.g., iritis, uveitis)"]
| Precautions | ["May cause allergic conjunctivitis (conjunctival hyperemia, itching, and tearing) in up to 10% of patients; discontinue if severe.","Can lead to ocular inflammation (iritis, uveitis).","Use caution in patients with severe cardiovascular disease (e.g., hypotension, bradycardia).","May cause tiredness, drowsiness, and decreased alertness; advise caution when driving or operating machinery.","Not recommended in patients with active intraocular inflammation (e.g., iritis, uveitis)."] |
Loading safety data…
| Monitor intraocular pressure; observe for systemic effects like hypotension or bradycardia. Fetal heart rate monitoring not routinely indicated. |
| Fertility Effects | No human data; animal studies show no adverse effects on fertility. |